Search
# Popular search #
0%
# Popular search #
Stock Code
603087.SHGan & Lee Pharmaceuticals Announced First Participant Dosed in a Phase 3 Clinical Study (OPTIMUM-2) of Bofanglutide (GZR18) injection in Chinese Patients with Type 2 Diabetes Mellitus
Insulin Glargine PDP Project Officially Approved at the National Level in Brazil
Gan & Lee Pharmaceuticals Announced First Participant Dosed in the US Phase 2 Clinical Study of Bofanglutide (GZR18) Injection for Overweight or Obesity
Gan & Lee Pharmaceuticals Announces Received Approval of Insulin Glargine Products in Malaysia
Gan & Lee Pharmaceuticals Announced First Participant Dosed in a Phase 3 Clinical Study (GRADUAL-1) of Bofanglutide (GZR18) injection in Chinese Patients with Overweight or Obesity
Gan & Lee Pharmaceuticals Announced Positive Phase 1 Results for Its Oral GLP-1 Receptor Agonist GZR18 Tablet in Healthy Participants, Demonstrating 4.16% Weight Reduction in Two Weeks
To be a world-class pharmaceutical company with focus on global business development
Registered in 20 countries
Products launched in 18 countries
Clinical trials conducted in 12 countries
Registered in 20 countries
Products launched in 18 countries
Clinical trials conducted in 12 countries
This website uses cookies to give users like yourself the best possible content and experience. For more information about your choices regarding cookies, please review our Privacy Policy .
The site you are about to visit is maintained by a third party who is responsible for its content.
This link is provided on the Gan & Lee website as a service to our visitors. Gan & Lee is not responsible for the privacy policy of any third-party websites. Gan & Lee encourages visitors to read the privacy policy of every website that you may visit.
